Droperidol in acutely agitated patients. A double-blind placebo-controlled study. 1977

A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent

Forty-one acutely agitated patients received an i.v. injection of 4 ml of a double blind solution containing either 10 mg of droperidol or placebo. The need for further medication (5 mg of haloperidol after 3 minutes or individually adapted psychotropics after 30 minutes) was used as a parameter for the evaluation of the results. Three minutes after the injection, haloperidol was needed by only six out of 19 patients of the droperidol group, but by 19 patients of the control group. Thirty minutes after the first injection, further medication was needed by only four droperidol patients and 10 placebo patients. No side effects could be attributed to the double blind medication.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004329 Droperidol A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) Dehydrobenzperidol,Dehidrobenzperidol,Droleptan,Inapsine
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
January 2013, Annals of emergency medicine,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
May 2013, Annals of emergency medicine,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
January 2009, Journal of the American Medical Directors Association,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
December 2016, British journal of clinical pharmacology,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
April 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
January 2003, Neurology,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
October 2021, Lancet (London, England),
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
July 1984, The Journal of clinical psychiatry,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
June 1979, Archives of general psychiatry,
A M van Leeuwen, and J Molders, and P Sterkmans, and P Mielants, and C Martens, and C Toussaint, and A M Hovent, and M F Desseilles, and H Koch, and A Devroye, and M Parent
April 2007, International journal of geriatric psychiatry,
Copied contents to your clipboard!